Microbial-derived trimethylamine N-oxide (TMAO) correlates with improved efficacy of immunotherapy in TNBC by inhibiting tumor growth through activation of CD8 + T-cell-mediated antitumor immunity. The gene discussed is CD8A; the disease is neoplasm.